Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Therapeutic Potential of Metabogenic and Nutriceutical Supplements in Duchenne Muscular Dystrophy Explored

Impaired cellular energy metabolism has been widely reported as a key element in dystrophin-deficient muscle degeneration, one of the most significant aspects of Duchenne Muscular Dystrophy (DMD). In a review entitled “Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy,” the authors present…

New Wellstone Muscular Dystrophy Center to Open at UT Southwestern

UT Southwestern has been awarded a $7.8 million, five-year grant to establish the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, with a special focus on inherited Duchenne muscular dystrophy (DMD). “UT Southwestern is the perfect environment for the Wellstone Center. We can merge cutting-edge science with clinical application,” said Dr.

Top 10 Muscular Dystrophy Articles of 2015

Throughout 2015, Muscular Dystrophy News covered the latest developments in science, research, and advocacy news in muscular dystrophy. As the year comes to an end, here are the 10 articles most widely read by Muscular Dystrophy News readers, each with a brief summary of the developments that made them of such…

2 Duchenne Muscular Dystrophy Protein Biomarkers Identified

Researchers have identified two promising biomarkers for the noninvasive monitoring of Duchenne muscular dystrophy (DMD) disease progression or regression, although more research is necessary. The paper, titled “Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients,” was published in Proteomics-Clinical Applications. Duchenne muscular dystrophy…

New DMD and Other Pediatric Disease Therapies Are Goal of Crowdfunding Campaign

SOM Biotech announced the start of its first crowdfunding campaign to initiate new R&D projects into rare pediatric diseases, including Duchenne muscular dystrophy (DMD). The company, headquartered at the Barcelona Science Park (PCB), aims to raise at least $300,000 to be divided evenly among five rare childhood diseases: DMD, cystic fibrosis, Gaucher’s disease (…

CITGO and Muscular Dystrophy Association Partnership Raises Over $30,000 in Arkansas

CITGO Petroleum Corporation announced it has partnered with the Muscular Dystrophy Association (MDA) to support its MDA Arkansas Chapter “Passport to a Cure” event. The Hollywood-themed event collected more $30,000 in funds, which will be used to benefit research and local families dealing with the neuromuscular disease. The MDA currently serves over 800 people in…

CITGO Helps Muscular Dystrophy Association Raise $350,000 in Wisconsin

CITGO Petroleum Corp. joined its marketers and retailers across Wisconsin in supporting Muscular Dystrophy Association (MDA) fund-raising events this year, helping to raise over $350,000 to benefit local MDA chapters and fund research into neuromuscular diseases. CITGO employees and its community of marketers and retailers have sponsored the MDA for almost 30 years,…

Study Traces Molecular Pathway Leading to Muscle Regeneration

University of Louisville researchers have discovered that a mechanism involved in stem-cell renewal pathways and muscle tissue regeneration, with implications in muscular dystrophy research. The study, titled “TRAF6 regulates satellite stem cell self-renewal and function during regenerative myogenesis,” was published in the Journal of Clinical Investigation. In muscle injury a…